Subscribe To

Price Alert Latest News Economic Calendar News

JAZZ / Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting

Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting

Data from six abstracts to be presented, including new long-term Phase 3 results and two real-world analyses of U.S. caregiver-reported seizure and non-seizure outcomes in patients prescribed Epidiolex ® (cannabidiol) DUBLIN , Nov. 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex ® (cannabidiol) oral solution presentations, including three late-breaking abstracts, will be shared at the upcoming 2022 American Epilepsy Society (AES) annual meeting, which will be held December 2-6, 2022, in Nashville, TN. "We understand the significant, lifelong implications of severe, childhood-onset epilepsy on both patients and their families. Read More

Demo Live Account See Partner Details

Content Topics

JAZZ

Pharmaceuticals

Present

Data

Demonstrating

Advancements

Epilepsy

Outcomes

American

Society

Annual

Meeting

Stock

Posted: Nov 28 2022, 08:09

Author Name: PRNewsWire

JAZZ News

By Zacks Investment Research
October 26, 2023

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS). But which of these two

By Zacks Investment Research
October 17, 2023

Jazz (JAZZ) Soars 5.3%: Is Further Upside Left in the Stock?

Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stoc

By Zacks Investment Research
October 10, 2023

JAZZ or ZTS: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Jazz Pharmaceuticals (JAZZ) or Zoetis (ZTS). But which of the

By Zacks Investment Research
September 22, 2023

Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze

The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activit

By Zacks Investment Research
September 8, 2023

Why Is Jazz (JAZZ) Up 0.4% Since Last Earnings Report?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

By Proactive Investors
August 30, 2023

Pharmaceutical cannabis sales surge, clinical trials seeing broader disease focus

The global pharmaceutical cannabis market is poised for significant growth, projected to swell by 23% by 2027, mostly from one company but with other

By Zacks Investment Research
August 10, 2023

Wall Street Analysts See a 51.66% Upside in Jazz (JAZZ): Can the Stock Really Move This High?

The consensus price target hints at a 51.7% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly e

By Zacks Investment Research
August 9, 2023

Jazz (JAZZ) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2023, it could be worth lo

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.